Taken together, our findings support the notion that overexpression of DAX1 in cervical cancer allows for aberrant binding to the GSK3β promoter, enhancing transcriptional inhibition of GSK3β, which then inhibits the degradation of β-catenin. Here, NR0B1 is linked to cervical carcinoma.